Efficacy of External Trigeminal Nerve Stimulation for Treatment of ADHD

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is a large multisite randomized clinical trial to asses the efficacy of external trigeminal nerve stimulation (TNS), a novel, minimal risk, non-invasive neuromodulation treatment, for ADHD in children ages 7-12 years old (N=180). Study hypotheses address potential differences in ADHD symptoms over 4 weeks treatment with active vs. sham TNS in an expanded multi-site investigation; whether resting state fronto-parietal connectivity mediates TNS impact on ADHD symptoms; if changes in fronto-parietal activation, as measured by electroencephalography (EEG), predict TNS-related treatment outcomes; and whether a baseline cognitive profile similarly predicts response to TNS therapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 7
Maximum Age: 12
Healthy Volunteers: f
View:

• male and female children ages 7 to 12 years with DSM-5 ADHD, any current presentation, as determined by diagnostic interview, Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS), and clinical interview;

• total score \>= 24 on baseline ADHD-RS;

• CGI-S score at baseline \>= 4;

• no current medication with CNS effects (Participants previously on psychostimulant medication will be required to be not optimally treated and off medication for one week or 5 half-lives for all other medications); stable use of supplements will be permitted;

• parents able and willing to monitor proper use of the stimulation device and complete all required rating scales;

• estimated Full Scale IQ \>= 80 based on WASI subtests;

• parent and participant able to complete rating scales and other measures in English;

• able to cooperate during EEG

Locations
United States
California
University of California, Los Angeles
RECRUITING
Los Angeles
Washington
Seattle Children's Hospital
RECRUITING
Seattle
Contact Information
Primary
Andrea Dillon, Ph.D.
andreadillon@mednet.ucla.edu
(310) 825-3757
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2026-01-31
Participants
Target number of participants: 280
Treatments
Experimental: Active eTNS
Following screening and determination of eligibility , participants at baseline are randomized to receive 4 weeks nightly treatment with active eTNS. Positive responders will be invited to participate in a 12-month open-label continuation phase.
Sham_comparator: Sham eTNS
Following screening and determination of eligibility, participants at baseline are randomize to receive 4 weeks nightly treatment with sham eTNS. At conclusion of the double-blind phase, participants randomized to sham will be provided an opportunity to receive an additional 4 weeks nightly treatment with active eTNS. Positive responders to active eTNS will be invited to participate in a 12-month open-label continuation phase.
Sponsors
Leads: University of California, Los Angeles
Collaborators: National Institute of Mental Health (NIMH)

This content was sourced from clinicaltrials.gov